Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis

Background: Rituximab (RTX), an anti-CD 20 monoclonal antibody is one of the first line biological disease-modifying anti-rheumatoid drug indicated for the treatment of rheumatoid arthritis (RA) in patient's refractory to conventional Synthetic DMARDs (csDMARDs). Limited data are available abou...

Full description

Bibliographic Details
Main Authors: Arun Hegde, Vivek Vasdev, Krishnan Shanmuganandan, Kavita Singh, Sivasami Kartik, Abhishek Kumar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Indian Journal of Rheumatology
Subjects:
Biosimilar
csDMARDs
immunoglobulin
Indian
rheumatoid arthritis
Rituximab
Online Access:http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2018;volume=13;issue=1;spage=20;epage=25;aulast=Hegde

Internet

http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2018;volume=13;issue=1;spage=20;epage=25;aulast=Hegde

Similar Items